Valuation: Astellas Pharma Inc.

Market Cap 3,846B 23.79B 20.9B 19.26B 18.01B 33.77B 2,245B 34.39B 231B 89.49B 1,107B 89.36B 87.4B P/E 2027 *
11x
P/E 2028 * 11.7x
Enterprise Value 3,744B 23.16B 20.34B 18.74B 17.52B 32.87B 2,185B 33.47B 225B 87.1B 1,077B 86.97B 85.06B EV / Sales 2027 *
1.67x
EV / Sales 2028 * 1.68x
Free-Float
98.88%
Yield 2027 *
3.75%
Yield 2028 * 3.87%
1 day-0.90%
1 week-1.64%
Current month-6.70%
1 month-5.03%
3 months-17.26%
6 months-1.19%
Current year-0.45%
1 week 13.04
Extreme 13.04
13.79
1 month 12.82
Extreme 12.8175
14.44
Current year 12.82
Extreme 12.8175
17.35
1 year 9.22
Extreme 9.22
17.35
3 years 8.37
Extreme 8.37
17.35
5 years 8.37
Extreme 8.37
18.22
10 years 8.37
Extreme 8.37
19.4
Manager TitleAgeSince
Chief Executive Officer 63 10/02/2023
Director of Finance/CFO 54 01/11/2023
Compliance Officer - 01/04/2025
Director TitleAgeSince
Chairman 66 10/02/2023
Director/Board Member 63 01/06/2019
Director/Board Member 58 01/06/2023
Change 5-day change 1-year change 3-year change Capi.($)
-0.90%-1.64% - - 23.91B
+1.56%+3.63%+43.68%+151.44% 996B
+1.57%+7.63%+61.43%+50.23% 580B
+2.98%+12.17%+30.98%+79.94% 415B
+5.66%-2.44%+22.01%+15.66% 326B
+1.34%+6.74%+32.63%+41.70% 280B
+1.09%+6.90%+37.22%+24.53% 284B
+1.32%+12.69%-27.48%-41.27% 210B
+1.29%+5.41%+26.93%+58.35% 190B
-0.36%+0.93%+17.92%+63.16% 155B
Average +1.54%+2.68%+27.26%+49.30% 381.86B
Weighted average by Cap. +1.93%+2.18%+35.22%+72.51%

Financials

2027 *2028 *
Net sales 2,244B 13.88B 12.19B 11.23B 10.5B 19.7B 1,310B 20.06B 135B 52.21B 646B 52.13B 50.99B 2,069B 12.8B 11.24B 10.36B 9.68B 18.16B 1,208B 18.5B 124B 48.13B 595B 48.06B 47.01B
Net income 350B 2.16B 1.9B 1.75B 1.64B 3.07B 204B 3.13B 21.02B 8.14B 101B 8.13B 7.95B 328B 2.03B 1.78B 1.64B 1.53B 2.88B 191B 2.93B 19.69B 7.63B 94.33B 7.62B 7.45B
Net Debt -103B -636M -558M -514M -481M -902M -59.99B -919M -6.17B -2.39B -29.57B -2.39B -2.33B -371B -2.29B -2.01B -1.86B -1.74B -3.25B -216B -3.31B -22.27B -8.62B -107B -8.61B -8.42B
Logo Astellas Pharma Inc.
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
Employees
14,099
Date Price Change Volume
26/06/26 US$13.23 -0.90% 76,392
24/06/26 US$13.35 +1.44% 214,678
23/06/26 US$13.16 -2.30% 290,219
22/06/26 US$13.47 +0.15% 380,311
18/06/26 US$13.45 +1.13% 213,798
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
2,147.00JPY
Average target price
2,400.00JPY
Spread / Average Target
+11.78%

Quarterly revenue - Rate of surprise